Seeking Alpha

Medtronic Inc. (MDT)

  • Apr. 8, 2014, 9:57 AM
    • Medtronic (MDT) spinal-cord stimulators implanted into the backs of three paraplegic patients helped them wiggle their toes and ankles, flex their legs and even stand independently for moments at a time.
    • The treatment worked in two patients who were previously unable to move or feel their lower bodies.
    • Researchers now intend to conduct a similar study with eight more patients, using a new device with more flexibility.
    | 1 Comment
  • Mar. 31, 2014, 4:34 AM
    • Edwards Lifesciences' (EW) Sapien XT heart valve, which can be inserted without open-heart surgery, outperformed a rival device from Medtronic (MDT) in a head-to-head comparison of 241 patients.
    • Sapien XT led to improved symptoms in patients, less leakage, was easier to insert and had a similar death rate to Medtronic's CoreValve, which, in a separate study, was shown to have better mortality figures than open-heart procedures.
    • While a previous version of the Sapien has generated disappointing sales, analysts believe that the market for the devices could eventually be worth $3B a year.
    | Comment!
  • Mar. 30, 2014, 1:36 AM
    • Medtronic's (MDT) CoreValve, an aortic valve that doctors can insert into the heart without cracking open ribs, cut death rates more than open-heart surgery in a trial of 747 people.
    • In the study, 14% of patients who received CoreValve died within a year of surgery vs 19% of those who had open-heart surgery.
    • "This is the type of evidence that changes guidelines and recommendations for care," says Mount Sinai Hospital's David Adams.
    • Edwards Lifesciences (EW) sells a similar device but it hasn't proved more effective than open-heart surgery and sales have been lower than expected. (PR)
    • Meanwhile, Medtronic plans to continue working on its Symplicity device for reducing blood pressure despite a surprising failure in trials. The company said "signals" in the data suggest that the treatment might benefit certain patients and that the procedure involving the device may not have been carried out correctly or completely during the testing. (PR)
  • Mar. 10, 2014, 8:41 AM
    • Wells Fargo upgrades Edwards Lifesciences (EW) to Outperform with a price target of $82 - $83, up from $67 - $69.
    • Catalysts for the upgrade include new transcatheter mitral valve implants that will boost 2016 revenue, an improved outlook for Sapien XT and upside potential from litigation with Medtronic (MDT) due to its infringement of two EW US patents.
    • EW closed Friday at $72.07.
    | Comment!
  • Mar. 7, 2014, 12:41 PM
    • North Carolina surgeon Stuart Meloy may have discovered a game changer for some women: a device that produces "orgasms on demand". He decided to pursue developing the product after witnessing a female patient's intense stimulation after he placed electrodes in her lower back for an undisclosed condition.
    • The device consists of two electrodes that will be surgically inserted into certain nerves in the spinal column and a cigarette pack-size signal generator implanted in the upper buttock. The user presses a remote control button for stimulation.
    • The device will be studied for women who have serious cases of orgasmic dysfunction where some women's brains interpret arousal as a fear response.
    • Medtronic (MDT) has signed on to conduct tests.
    • No decision on developing a mass market version has been disclosed.
  • Feb. 18, 2014, 9:13 AM
    • Medtronic's (MDT +0.2%) net profit slumps to $762M from $988M a year earlier, which included a tax benefit.
    • Earnings also fell because Medtronic took charges for the failed trial of a therapy for high-blood pressure. The charges and other one-time items hit Medtronic's income by $0.16 a share.
    • Sales breakdown: implantable cardioverter defibrillators flat at $655M; pacemakers -4% to $439M; structural heart products +3% to $281M; spinal products -1% to $744M; diabetes +16% to $436M.
    • Emerging markets revenues +10% to $521M.
    • Medtronic narrows its 2014 EPS guidance to $3.81-3.83 from a previous prediction of $3.80-3.85. The company still expects revenue growth of 3-4%. (PR)
    • Previous
    | Comment!
  • Feb. 18, 2014, 7:26 AM
    • Medtronic Inc. (MDT): FQ3 EPS of $0.91 in-line.
    • Revenue of $4.16B (+3.2% Y/Y) beats by $10M.
    • Press Release
    | Comment!
  • Feb. 18, 2014, 12:05 AM
  • Feb. 17, 2014, 5:30 PM
  • Jan. 28, 2014, 4:04 PM
    • The system was approved for use in the treatment of type B aortic dissections.
    • "Supported by the results of the U.S. Medtronic DISSECTION trial, the new indication expands treatment options for this challenging patient population by providing physicians with a minimally invasive alternative to open surgical repair and medical therapy."
    • Medtronic (MDT +0.2%) press release
    | Comment!
  • Jan. 21, 2014, 9:04 AM
    • Covidien (COV) says it will exit its OneShot renal denervation program, primarily in response to slower-than-expected development of the device's market.
    • Renal denervation devices are designed to help prevent the kidneys, which play an important role in regulating blood pressure, from contributing to hypertension.
    • The voluntary move comes after Medtronic (MDT) earlier this month said its experimental Symplicity renal denervation device failed to provide a benefit compared with a placebo procedure in a large clinical study.
    • COV expects to record related charges of $20M-$25M.
    | Comment!
  • Jan. 17, 2014, 2:10 PM
    • Medtronic (MDT +0.4%) says it received FDA approval, three months earlier than expected, to sell its CoreValve heart valve technology for patients too frail for traditional surgery approval.
    • The approval allows MDT to begin competing against Edwards Lifesciences (EW -5.1%), whose similar Sapien device has been approved for a wider range of patients, including those who are eligible for surgery, but who are considered at high risk for complications.
    • CoreValve is approved for patients with severe aortic stenosis who are too sick or frail to undergo open-heart surgery; in a clinical trial, patients receiving the device had a 25% rate of death or major stroke after one year vs. an estimated rate of 43% had the patients received medication therapy.
    | 1 Comment
  • Jan. 16, 2014, 7:50 AM
    • Medtronic (MDT) intends to appeal a jury's ruling that the company pay Edwards Lifesciences (EW) $392M after finding that Medtronic's CoreValve heart device willfully infringes patents that Edwards holds for its Cribier transcatheter.
    • The "willful breach" means that Edwards can seek increased damages of up to three times the amount awarded.
    • Edwards intends to ask a judge to stop Medtronic from selling CoreValve heart device in the U.S. The latter had planned to begin sales in April, pending FDA approval. Both companies' products are already sold outside the U.S. (PR)
    | Comment!
  • Jan. 9, 2014, 7:50 AM
    • Medtronic's (MDT) Symplicity renal denervation system for treating hypertension was ineffective in a clinical trial.
    • Not that it would seem to help much, but the study shows that there were no safety concerns with the device. (PR)
    | Comment!
  • Jan. 8, 2014, 9:16 AM
    • The FDA has accepted LabCorp's (LH) application for its diagnostic test to be used in the Phase 2B/3 "GENETIC-AF" trial of ARCA Biopharma's (ABIO) Gencaro drug for treating patients with atrial fibrillation.
    • Patient enrollment for the testing, in which ARCA is collaborating with Medtronic (MDT) also, is due to begin this quarter.
    • ARCA's shares soar 21%. (PR)
    | 1 Comment
  • Jan. 6, 2014, 2:09 PM
    • McKesson (MCK -0.1%) upgraded to Strong Buy from Outperform at Raymond James.
    • DaVita (DVA +0.4%) upgraded to Outperform from Market Perform at Raymond James.
    • Idenix Pharmaceuticals (IDIX -0.3%) upgraded to Buy from Neutral at UBS.
    • Abbott Labs (ABT +1.5%) upgraded to Overweight from Equalweight at Morgan Stanley.
    • Medtronic (MDT +2%upgraded to Overweight from Neutral at JPMorgan. Price target is $69.
    • Vertex Pharmaceuticals (VRTX +2.5%) upgraded to Buy from Neutral at UBS.
    • Ocera Therapeutics (OCRX +2.7%) upgraded to Outperform from Market Perform at BMO.
    • Boston Scientific (BSX +3.2%upgraded to Overweight from Equalweight at Morgan Stanley.
    • Exelixis (EXEL +4.6%) upgraded to Overweight from Neutral at Piper.
    • St. Jude Medical (STJ +3.8%) upgraded to Overweight from Equalweight at Morgan Stanley.
Visit Seeking Alpha's
MDT vs. ETF Alternatives
Company Description
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.